First results of the program AcSé Nivolumab including 16 patients with MMR‐P POLE‐mutated tumors showed an overall response rate of 50% in patients tumors harboring pathogenic exonucleasic domain mutations, all in advanced CRC. The gene discussed is POLE; the disease is colorectal carcinoma.